Senores Pharmaceuticals Ltd
Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities[1]
- Market Cap ₹ 2,323 Cr.
- Current Price ₹ 504
- High / Low ₹ 610 / 435
- Stock P/E 2,868
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 2.62 %
- ROE 0.78 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 262 days to 126 days
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of 1.67% over last 3 years.
- Earnings include an other income of Rs.6.85 Cr.
- Company has high debtors of 236 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Part of BSE IPO
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| 7.91 | 13.54 | 12.38 | 34.01 | |
| 6.89 | 12.38 | 14.16 | 34.08 | |
| Operating Profit | 1.02 | 1.16 | -1.78 | -0.07 |
| OPM % | 12.90% | 8.57% | -14.38% | -0.21% |
| 0.15 | 0.94 | 6.79 | 6.85 | |
| Interest | 0.20 | 0.56 | 2.14 | 2.71 |
| Depreciation | 0.57 | 0.71 | 0.93 | 2.04 |
| Profit before tax | 0.40 | 0.83 | 1.94 | 2.03 |
| Tax % | -110.00% | 18.07% | 38.14% | 60.10% |
| 0.84 | 0.68 | 1.20 | 0.81 | |
| EPS in Rs | 2.21 | 0.69 | 1.22 | 0.27 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 63% |
| TTM: | 175% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -1% |
| TTM: | -33% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 2% |
| Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| Equity Capital | 3.80 | 8.74 | 9.82 | 30.51 |
| Reserves | 5.67 | 24.95 | 29.11 | 137.61 |
| 3.71 | 14.75 | 60.66 | 94.12 | |
| 1.78 | 6.73 | 12.13 | 23.62 | |
| Total Liabilities | 14.96 | 55.17 | 111.72 | 285.86 |
| 1.69 | 1.59 | 7.77 | 24.09 | |
| CWIP | 2.71 | 3.17 | 11.33 | 18.47 |
| Investments | 1.45 | 11.69 | 8.23 | 81.58 |
| 9.11 | 38.72 | 84.39 | 161.72 | |
| Total Assets | 14.96 | 55.17 | 111.72 | 285.86 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| -2.87 | -24.06 | -47.78 | -62.82 | |
| -4.37 | -10.05 | 1.07 | -13.51 | |
| 8.50 | 33.88 | 45.33 | 86.68 | |
| Net Cash Flow | 1.25 | -0.23 | -1.38 | 10.35 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| Debtor Days | 10.61 | 225.63 | 463.77 | 236.21 |
| Inventory Days | 31.10 | 132.65 | 194.00 | 85.31 |
| Days Payable | 11.89 | 269.30 | 272.97 | 219.49 |
| Cash Conversion Cycle | 29.82 | 88.98 | 384.80 | 102.03 |
| Working Capital Days | 219.65 | 159.05 | 502.39 | 126.00 |
| ROCE % | 4.51% | 5.51% | 2.62% |
Documents
Announcements
-
Intimation Under Regulation 30(6) Of SEBI (LODR) Regulations, 2015.
1d - Investment of USD 1,252,800 in Senores Pharmaceuticals Inc.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
13 Jan - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2024.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
10 Jan - For Earnings Conference call scheduled to be held on January 23, 2025 at 04:30 P.M. (IST).
-
Board Meeting Intimation for Considering And Approving Unaudited Standalone And Consolidated Financial Results Of The Company For Quarter And Nine Months Ended December 31, 2024.
10 Jan - Board meeting to approve financial results on January 23, 2025.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
9 Jan - Senores Pharmaceuticals receives ANDA approval for Metoprolol and Hydrochlorothiazide tablets.
Business Overview:[1]
SPL is global research driven pharmaceutical company which develops and manufactures
pharmaceutical products for the Regulated Markets of US, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Company develops and manufactures specialty, underpenetrated and complex pharmaceutical products. It also manufactures criticalcare injectables and APIs